Streetbeat News

Stock Prices

SWTX

SpringWorks Therapeutics (NASDAQ:SWTX) reported Q2 2024 GAAP EPS of $(0.54), significantly beating the analyst estimate of $(1.13). The company also reported sales of $59.733 million, surpassing the estimate of $34.343 million.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 10:38 am

LQDA

Liquidia (NASDAQ:LQDA) reported Q2 2024 GAAP EPS of $(0.37), missing the $(0.34) estimate. Sales were $3.659M, missing the $9.451M estimate. Cash and equivalents totaled $133.1M.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 10:36 am

KMT

Kennametal has released its financial outlook for FY25, projecting sales between $2.0 billion and $2.1 billion, and adjusted EPS between $1.30 and $1.70. The company expects improved operating performance, offset by higher effective tax rates and currency headwinds. Pricing actions are anticipated to cover raw material costs, wages, and general inflation. Interest expense is projected at $27 million, with an adjusted effective tax rate of 27.5%. Free operating cash flow is expected to exceed 125% of adjusted net income, with primary working capital at 30% of sales by year-end. Capital spending is forecasted at $110 million.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 10:35 am

PRKS

United Parks & Resorts expects to deliver new records in revenue and adjusted EBITDA in 2024, driven by strong booking trends at Discovery Cove and increased group bookings. International visitation is also up compared to the previous year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 10:35 am

NI

NiSource (NYSE:NI) reported Q2 2024 adjusted earnings per share (EPS) of $0.21, surpassing the analyst consensus estimate of $0.16 by 31.25%. This represents a 90.91% increase from the $0.11 EPS reported in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 10:35 am

PRKS

United Parks & Resorts (NYSE:PRKS) reported Q2 2024 earnings per share (EPS) of $1.46, missing the analyst estimate of $1.55 by 5.81%. Sales were $497.593 million, also missing the estimate of $503.856 million by 1.24%. Despite the misses, EPS increased by 8.15% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 10:34 am

CVS

CVS Health has revised its full-year 2024 adjusted EPS guidance to $6.40-$6.65 from at least $7.00, which is below the consensus of $6.98. The revision is due to continued pressure in the Health Care Benefits segment, partially offset by strong performance in the Health Services and Pharmacy & Consumer Wellness segment.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 10:33 am

DT

Dynatrace shares are trading higher following a Q1 earnings beat.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 10:32 am

RXO

RXO (NYSE:RXO) reported Q2 2024 adjusted EPS of $0.03, beating the $0.02 estimate by 50%. However, sales of $930 million missed the $934.146 million estimate by 0.44%, marking a 3.43% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 10:32 am

GHM

Graham (NYSE:GHM) reported Q1 2025 adjusted EPS of $0.33, beating the $0.15 estimate by 120%. However, sales of $49.951M missed the $50.100M estimate by 0.30%, though they increased by 5.01% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 10:31 am